CN1449740A - Virus-killing alpha interferon series medicinal cosmetics - Google Patents
Virus-killing alpha interferon series medicinal cosmetics Download PDFInfo
- Publication number
- CN1449740A CN1449740A CN 03127025 CN03127025A CN1449740A CN 1449740 A CN1449740 A CN 1449740A CN 03127025 CN03127025 CN 03127025 CN 03127025 A CN03127025 A CN 03127025A CN 1449740 A CN1449740 A CN 1449740A
- Authority
- CN
- China
- Prior art keywords
- alpha
- cosmetics
- interferon
- cream
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Cosmetics (AREA)
Abstract
The present invention provides an alpha-interferon series medicinal cosmetics with the action of killing virus, in which alpha-interferon content in every gram of cosmetic is 0.0001-0.05 mg, its active unt is 10000 IU-5000000 IU/g, and its purity is 85%-99.52%. The described alpha-interferon includes 23 subtype series alpha-interferons belonged to alpha, alpha 2a, alpha 2b and others. Said alpha-interferon is combined in the cosmetics, and can be made into compound functional medicine series cosmetics. These cosmetics can be applied on the face, eye portion, mouth portion, nasal part periphery and hand portion, and can inhibit the replication of virus on those regions, so that it can prevent viral infection and propagation, including SARS virus.
Description
Technical field:
The present invention relates to a kind of cosmetics that can kill virus comprise SARS virus, say clearly to provide a kind of interferon-alpha medicine series cosmetics, belong to medicine serial cosmetics and fabricating technology field with kill virus effect.
Background technology:
Virus, particularly SARS virus is owing to be to propagate pathogenic by approach such as respiratory tract (nose-mouth) and contacts, therefore, controlling its propagation relatively is difficult to carry out, usually adopt drug spray, collunarium etc., but very not comprehensively not thoroughly, seeking a kind of method of prophylaxis of viral infections effectively easily becomes the task of top priority.And cosmetics are directly to be applied on people's the skin, have real-time action function, can be used as the antiviral good measure of medicine of implementing, and do not see that by retrieval having antiviral particularly reports the serial cosmetics of SARS virus effect at present.
Summary of the invention:
The purpose of this invention is to provide a kind of interferon-alpha medicine series cosmetics, have multiple functions such as antiviral and skin protection with kill virus effect.
Interferon-alpha has the effect of broad-spectrum antiviral, being one group can induce a series of cell intrinsic proteins to express, then bring into play the cytokine of antiviral, antiproliferative and the effect of adjusting immunne response, after interferon acts on the interferon receptors of cell, through a series of physiological process such as signal conduction, make cell synthesize at least three kinds of antiviral proteins: protein kinase, PDE and 2-5A synzyme, these enzymes are by degraded mRNA, the proteic antivirus action that synthesized of link blocking virus such as suppress that the extension of polypeptide chain and inhibition are translated.Interferon-alpha combined with cosmetics make the medicine serial cosmetics, can be used to prevent virus diseases such as SARS, the route of transmission that blocking-up causes because of hands and contact skin.
Concrete technical solution of the present invention is as follows: with interferon-alpha is that main ingredient is added in the cosmetics by homogenizing technology, wherein, the interferon-alpha content of every gram cosmetics is that 0.0001-0.05mg, active unit are 10,000 IU-500, ten thousand IU/ grams, and purity is 85%-99.52%.
Described interferon-alpha or (IFN-α) can be the recombined human alpha-interferons with the gene engineering method preparation, also can be that alpha-interferon is meant α, α with the people source LeIF of human leukocyte preparation
2a, α
2b... the serial alpha-interferon of 23 hypotypes under waiting.
Technical process is as follows:
At first that interferon-alpha stock solution preparation back is standby, oil phase and water two component raw material that will produce cosmetics again heat respectively, and emulsifying postcooling to 45 ° is added the interferon-alpha stock solution for preparing, and is stirred to uniform temperature through vacuum outgas and gets final product.
The present invention relates to comprise: emollient cream, cold cream, day cream, late frost, vanishing cream, emulsion, eye cream, hand cream, chapstick, floral water, shrinkage water, astringent by the skin type product that interferon-alpha and other cosmetic material are made; Cleaning class cosmetics comprise: cleansing cream, Cleansing Foam, bath foam, shaving product; Functional cosmetics comprises: Skin whitening care cosmetics, preserving moisture and protecting skin product, anti-acne skin care item, anti-antiperspirant skin care item; Cosmetics comprise: vanishing cream, XIANGFEN, facial film, lip pomade, kermes.
Good effect of the present invention is: interferon-alpha is made the functional medicine serial cosmetics of compound recipe in the cosmetics combination, be applied in around face, eye, mouth, the nose and hand, can suppress virus duplicating at these positions, cut off the approach that virus is propagated by hands and contact skin, using method is simple, meet the daily living-hygienic custom of people, prevented virus to comprise the transmission of infection of SARS virus in the time of skin protection.
The specific embodiment:
Embodiment 1
The alpha-interferon hand cream:
A, spermol 6.0%, refining Cera Flava 6.3%, Oleum Helianthi 39.0%, ermine oil 6.5%;
B, methyl hydroxybenzoate 0.1%, deionized water surplus;
C, essence are an amount of;
D, alpha-interferon 0.00001～0.005%;
Stabilizing agent is an amount of; Other should meet the cosmetic industry relevant regulations.
Technology: the A component in 70-80 ℃ of dissolving, is added the emulsifying of B component, be cooled to 37 ℃, add C, D component, homogenizing is even.
Embodiment 2
Alpha-interferon emollient cream:
A, ZY-92 (emulsifying agent) 2.0%, ZY-921 (emulsifying agent) 3.0%, C
16-
18OH (16-18 alcohol) 3.0%, white oil 10.0%, DC-200 (emulsifying agent) 0.5%, stearic acid 2.0%, BTH (antioxidant) 0.2%;
B, glycerol 3.0%, HANSHENGJIAO 0.1%, EDTA-2Na (disodiumedetate) 0.1% water surplus;
C, triethanolamine 0.25%, extremely U.S. 0.2%,
D, alpha-interferon 0.00001～0.005%;
Stabilizing agent is an amount of; Other should meet the cosmetic industry relevant regulations.
Technology: the A component is dissolved in 70-80 ℃ of water-bath, the B component with glycerol with HANSHENGJIAO and second two by the tetraacethyl disodium back water-bath dissolving that is uniformly dispersed, A is poured among the B, emulsifying, the cooling back adds C, D component, homogenizing is even.
Embodiment 3
The alpha-interferon eye cream
A, PEA (emulsifying agent) 2.0%, IPP (isopropyl palmitate) 5.0%, synthetic squalane 2.0%, C
16-
180H (16-18 alcohol) 1.0%;
B, AVC (acrylate copolymer) 1.0%;
C, Polylift (Firm agent) 3.0%, Fermiskin (wrinkle removing agent) 1.0%, extremely U.S. 1.0%, water surplus;
D, alpha-interferon 0.00001～0.005%;
Stabilizing agent is an amount of; Other should meet the cosmetic industry relevant regulations.
Technology: with the B component with part deionized water heating for dissolving, stir, the A component is dissolved in 70-80 ℃ of water-bath, the A component is poured in the B component, stirs, and is cooled to 45 ℃, adds B, C, component, stirring gets final product.
Embodiment 4
The alpha-interferon handwashing liquid
A, AC-208 (emulsifying agent) 30.0%, 6501 (cocamido propyl betaine) 6.0%, AES-70 (polyoxyethylenated alcohol sodium sulfate) 5.0%, amine oxide 7.0%, PX (chloroxylenol) 0.2%, IG-300 (triclosan) 0.5%;
B, citric acid 0.2%;
C, DMDMH (antiseptic) 0.3%;
Water surplus
D, alpha-interferon 0.00001～0.005%; Other should meet the cosmetic industry relevant regulations.
Technology: C, B component are dissolved in 70-80 ℃ of water-bath, and emulsifying is cooled to 45 ℃, adds B, D component, and stirring gets final product.
Claims (4)
1, a kind of interferon-alpha medicine series cosmetics with kill virus effect, it is characterized in that: the ingredient of cosmetics is interferon-alpha, the content of its every gram cosmetics interferon-alpha is that 0.0001-0.05mg, active unit are 10,000 IU-500, ten thousand IU/ grams, and purity is 85%-99.52%.
2, a kind of serial cosmetics according to claim 1, it is characterized in that described interferon-alpha comprise recombined human alpha-interferon with gene engineering method preparation, with the people source LeIF of human leukocyte preparation, alpha-interferon is meant α, α
2a, α
2b... the serial alpha-interferon of 23 hypotypes under waiting.
3, a kind of preparation technology with interferon-alpha medicine series cosmetics of kill virus effect is characterized in that being finished by following steps:
At first that interferon-alpha stock solution preparation back is standby, oil phase and water two component raw material that will produce cosmetics again heat respectively, and emulsifying postcooling to 45 ° is added the interferon-alpha stock solution for preparing, and is stirred to uniform temperature through vacuum outgas and gets final product.
4, serial cosmetics according to claim 1 is characterized in that described cosmetics comprise the skin type product: emollient cream, cold cream, day cream, late frost, vanishing cream, emulsion, eye cream, hand cream, chapstick, floral water, shrinkage water, astringent; Cleaning class cosmetics: cleansing cream, Cleansing Foam, bath foam, shaving product; Functional cosmetics: Skin whitening care cosmetics, preserving moisture and protecting skin product, anti-acne skin care item, anti-antiperspirant skin care item; Cosmetics: vanishing cream, XIANGFEN, facial film, lip pomade, kermes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03127025 CN1449740A (en) | 2003-05-14 | 2003-05-14 | Virus-killing alpha interferon series medicinal cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03127025 CN1449740A (en) | 2003-05-14 | 2003-05-14 | Virus-killing alpha interferon series medicinal cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1449740A true CN1449740A (en) | 2003-10-22 |
Family
ID=28684455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03127025 Pending CN1449740A (en) | 2003-05-14 | 2003-05-14 | Virus-killing alpha interferon series medicinal cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1449740A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651271A4 (en) * | 2003-04-01 | 2006-11-08 | Intermune Inc | Compositions and methods for treating coronavirus infection and sars |
| CN101172091B (en) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same |
| CN104622777A (en) * | 2015-02-15 | 2015-05-20 | 广州赛莱拉干细胞科技股份有限公司 | Leukocyte extract and preparation method and application thereof |
| CN109819650A (en) * | 2017-09-25 | 2019-05-28 | 春布里泽·格奥尔基·格奥尔基耶维奇 | With antiviral and antibacterial activity thermostable composite and application thereof |
| CN111012717A (en) * | 2020-02-19 | 2020-04-17 | 江南大学附属医院 | Antiviral vitamin E cream composite preparation |
| CN111184666A (en) * | 2020-02-19 | 2020-05-22 | 江南大学附属医院 | Antiviral urea cream compound preparation |
-
2003
- 2003-05-14 CN CN 03127025 patent/CN1449740A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651271A4 (en) * | 2003-04-01 | 2006-11-08 | Intermune Inc | Compositions and methods for treating coronavirus infection and sars |
| CN101172091B (en) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same |
| CN104622777A (en) * | 2015-02-15 | 2015-05-20 | 广州赛莱拉干细胞科技股份有限公司 | Leukocyte extract and preparation method and application thereof |
| CN109819650A (en) * | 2017-09-25 | 2019-05-28 | 春布里泽·格奥尔基·格奥尔基耶维奇 | With antiviral and antibacterial activity thermostable composite and application thereof |
| CN111012717A (en) * | 2020-02-19 | 2020-04-17 | 江南大学附属医院 | Antiviral vitamin E cream composite preparation |
| CN111184666A (en) * | 2020-02-19 | 2020-05-22 | 江南大学附属医院 | Antiviral urea cream compound preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100347651B1 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| US6040347A (en) | Treatment of seborrhoea/cutaneous disorders with octoxyglycerol | |
| JPH08502074A (en) | Tissue protection and regeneration composition | |
| US4256763A (en) | Treatment of herpes simplex infections and acne | |
| AU2004251720B2 (en) | Method for treatment of sores and lesions of the skin | |
| CN1814279A (en) | Regenerated human alkali fiber-cell growth factor gel former and preparing method | |
| US20180353448A1 (en) | Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne | |
| CN1449740A (en) | Virus-killing alpha interferon series medicinal cosmetics | |
| US20060105057A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| KR20000046633A (en) | Composition for treatment of atopic dermatonosis | |
| US5036095A (en) | Therapeutic use of DMDM Hydantoin | |
| DE69932922T2 (en) | USE OF ALKANIC ACID-CONTAINING COMPOSITIONS FOR THE TREATMENT OF NAIL PLUG DISEASES | |
| CN1753949A (en) | Poloxamer emulsion preparations | |
| CA1112164A (en) | Therapeutic selenium compositions and the use thereof | |
| JP3631245B2 (en) | Use of hymenoptera venom for the manufacture of a medicament for the treatment of DNA virus infection | |
| Ikić et al. | Interferon reduces recurrences of basal cell and squamous cell cancers | |
| KR20200044434A (en) | Composition for treating intractable ulcer comprising substance P | |
| CN1062147C (en) | Cuochuangjing-external use medicine for treating acne | |
| CA2679939A1 (en) | Composition and method for treating papilloma virus and equine sarcoids | |
| US20050276766A1 (en) | Methods and compositions for increasing skin remodeling | |
| CN1460464A (en) | Interferon series daily-use chemical products with virus-killing action and its production process | |
| US20040022868A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| CN114344466B (en) | Use of PCSK9 inhibitors for the preparation of products for the treatment of keratinization disorders | |
| US3171782A (en) | Oral compositions comprising lysozyme and vitamin b6 | |
| TWI792375B (en) | Derived peptides of lactoferrin and a use thereof for promoting and/or increasing lipid synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |